← Research LibraryThe BriefFY2025 10-K · headline figures audited against SEC data
Surrozen, Inc./DE: Revenue declined 67.4% to $3.477M from $10.65M. Net loss widened to $242M from $63.56M. Free cash flow outflow widened to $30.37M from $17.65M. Operating margin contracted 97089 bps to -1210.58%. Surrozen, Inc./DE's annual comparison also shows capital spending grew faster than revenue; the balance-sheet screen falls in the distress range and requires business-model context; the earnings-quality screen is grey.
The read at a glance✓ Audited against SEC data
- Growth — Revenue declined 67.4% to $3.477M from $10.65MWatch
- Profitability — Net loss widened to $242M from $63.56MWatch
- Cash flow — Free cash flow outflow widened to $30.37M from $17.65MWatch
- Margins — Operating margin contracted 97089 bps to -1210.58%Watch
- Accounting — Distress-range screen needs contextWatch
- Insiders — 28 purchases and 5 salesOK
Business
In pursuit of our goal to develop a portfolio of Wnt product candidates that can repair tissue damage and regenerate functional tissues for patients, we are continuing to expand our platform through the development of novel technologies and capabilities required to research, develop, manufacture and ultimately commercialize therapeutic products that address unmet medical needs.
Where the revenue comes from
Fiscal 2025, as Surrozen, Inc./DE reports it. History and quarterly detail are in the app.
- Research Service Revenue$3.5M
Leadership changes
From Surrozen, Inc./DE's own filings, the day they're filed.
- Tim Kutzkey · Director · appointmenteff. 2025-03-26
- Tim Kutzkey · directors · departureeff. 2024-06-30
- Charles Williams · Chief Operating Officer · appointmenteff. 2024-02-01
Latest filings
- 10-Q · Quarterly report2026-08-06
- 8-K · Company announcement2026-08-06
- 8-K · Company announcement2026-05-14
- 10-Q · Quarterly report2026-05-06
- 8-K · Company announcement2026-05-06
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Surrozen, Inc./DE, every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.